<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04574791</url>
  </required_header>
  <id_info>
    <org_study_id>MAUS20d635</org_study_id>
    <nct_id>NCT04574791</nct_id>
  </id_info>
  <brief_title>Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee Arthroplasty</brief_title>
  <official_title>Addition of Muscle Relaxants in a Multimodal Analgesic Regimen for Analgesia After Primary Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rothman Institute Orthopaedics</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rothman Institute Orthopaedics</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, cluster-randomized, two-arm, comparative study aimed at determining&#xD;
      whether addition of tizanidine ( an oral muscle relaxant) to a multimodal pain regimen&#xD;
      following primary TKA reduces opioid consumption.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">September 3, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>opioid consumption (MME) postoperatively</measure>
    <time_frame>the first 14-days postoperatively</time_frame>
    <description>Primary outcome is patients total opioid consumption for the first 14 days after surgery.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Pain, Postoperative</condition>
  <arm_group>
    <arm_group_label>Multimodal Pain Regimen</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients &lt;65 years and 15 mg IV Q8h for patients who are &gt;65 years, supplemented with PRN oxycodone and tramadol.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multimodal Pain Regimen + Tizanidine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>current standard of care post-operative pain regimen in the hospital, which comprises of standing doses of oral acetaminophen 975 mg three times a day, gabapentin 300 mg two times a day, and intravenous ketorolac 30 mg three times a day for patients &lt;65 years and 15 mg IV Q8h for patients who are &gt;65 years, supplemented with PRN oxycodone and tramadol supplemented with standing doses of oral tizanidine in the hospital and for 14 days after discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TiZANidine 2 MG Oral Capsule</intervention_name>
    <description>Tizanidine 2 mg q8h (standing; # 42 tablets) + Multimodal pain regimen</description>
    <arm_group_label>Multimodal Pain Regimen + Tizanidine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  - Patients undergoing unilateral primary TKA with underlying diagnosis of&#xD;
             osteoarthritis.&#xD;
&#xD;
          -  ASA I - III&#xD;
&#xD;
          -  Spinal anesthesia&#xD;
&#xD;
          -  All patients will have a total knee arthroplasty utilizing a medial parapatellar&#xD;
             approach with cruciate sacrificing implants and patellar resurfacing. A tourniquet&#xD;
             will be used in all cases.&#xD;
&#xD;
          -  Men and women between 18 and 80 years who are willing and able to provide informed&#xD;
             consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Opioid use greater than 10 mg/day morphine equivalents continuously for one month&#xD;
             within 3 months preoperatively&#xD;
&#xD;
          -  Inability to take/allergy to the protocol medications&#xD;
&#xD;
          -  Contraindication to regional anesthesia&#xD;
&#xD;
          -  Non-English speaking&#xD;
&#xD;
          -  ASA IV or greater&#xD;
&#xD;
          -  Psychiatric or cognitive disorders&#xD;
&#xD;
          -  Allergy/contraindications to protocol medications.&#xD;
&#xD;
          -  Renal insufficiency with Cr &gt; 2.0 or hepatic failure&#xD;
&#xD;
          -  Sensory/motor disorder involving the operative limb&#xD;
&#xD;
          -  PCS score &gt;20&#xD;
&#xD;
          -  Patients with severe cardiac or neurological conditions precluding the use of study&#xD;
             medications&#xD;
&#xD;
          -  Patients using anticoagulation other than aspirin for the 14-day period after&#xD;
             discharge&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Rothman Orthopaedic Institute</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 29, 2020</study_first_submitted>
  <study_first_submitted_qc>September 29, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2020</study_first_posted>
  <last_update_submitted>September 29, 2020</last_update_submitted>
  <last_update_submitted_qc>September 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscle Hypotonia</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tizanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

